Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

Germo Gericke, Chief Medical Officer at Ariceum Therapeutics, said: This is an important milestone, not only for Ariceum but for the whole field of targeted radionuclide cancer treatments.

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...